Protection from enteric pathogens by beneficial microbes

通过有益微生物预防肠道病原体

基本信息

  • 批准号:
    8256331
  • 负责人:
  • 金额:
    $ 25.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-18 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The host and its commensal microbiota generally maintain a peaceful coexistence; however, a few bacteria disrupt immune homeostasis and cause disease. For example, attaching and effacing (A/E) enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC) cause diarrheal diseases that affect more than 2 billion people and kill 1.5 million children annually. Commensal bacteria can protect the host from disease caused by enteric pathogens; however, the mechanisms by which this occurs are poorly understood. We recently found that a single oral dose of commensal Bacillus subtilis or Bacillus formis spores can protect mice from disease caused by the A/E pathogen, Citrobacter rodentium. In contrast, a closely related commensal Bacillus licheniformis, and two B. subtilis mutants, hag and espH, did not protect the host. Because the single dose of protective Bacillus spp. is given 24 hr prior to pathogenic C. rodentium, protection is not likely due to initiation of an adaptive immune response, but is more likely due to an innate anti-inflammatory immune response. Alternatively, Bacillus spp. could protect from disease by directly interfering with localization of C. rodentium to the intestinal epithelium. In Aim 1 we will use in vivo bioluminescence imaging (IBIS) to determine if protective Bacillus spp. alter the colonization site of pathogenic C. rodentium. One of the non-protective B. subtilis mutants is deficient in flagellin, a ligand for TLR5, and another is deficient in exopolysaccharide, presumed ligand for TLR2, and in Aim 2 we will use TLR agonists and TLR knockout mice to determine if protection is mediated through TLR. Similarly, we will use Nod-like receptor (NLR) agonists and knockout mice to determine if protection is mediated through NLR. In Aim 3, we will test the possibility that B. subtilis mediates protection through T regulatory cells. PUBLIC HEALTH RELEVANCE: We investigate a means of protecting against enteric pathogens that cause diarrheal disease by a single oral dose of spores from a commensal-like (beneficial) bacterium. The experiments are designed to determine the mechanism by which this protection occurs. We investigate the possibilities that the commensal bacterium interferes with colonization of the enteric pathogen, or stimulates an anti-inflammatory response in the host.
描述(由申请人提供):寄主及其共生菌群总体上保持和平共处;然而,少数细菌会破坏免疫稳态并引起疾病。例如,附着和清除(A/E)肠致病性和肠出血性大肠杆菌(EPEC和EHEC)导致腹泻疾病,每年影响20多亿人,造成150万儿童死亡。共生菌可以保护宿主免受肠道病原体引起的疾病;然而,人们对这种情况发生的机制知之甚少。我们最近发现,单次口服共生枯草芽孢杆菌或形式芽孢杆菌孢子可以保护小鼠免受a /E病原体,啮齿柠檬酸杆菌引起的疾病。相比之下,一种密切相关的共生地衣芽孢杆菌和两种枯草芽孢杆菌突变体hag和espH没有保护宿主。由于单剂量保护性芽孢杆菌比致病性啮齿c早24小时给予,保护不太可能是由于启动适应性免疫反应,而更可能是由于先天的抗炎免疫反应。另外,芽孢杆菌可以通过直接干扰啮齿鼠肠上皮的定位来预防疾病。在目标1中,我们将使用体内生物发光成像(IBIS)来确定保护性芽孢杆菌是否会改变致病性啮齿c的定植位置。其中一个非保护性枯草芽孢杆菌突变体缺乏鞭毛蛋白(TLR5的配体),另一个缺乏外多糖(TLR2的配体),在Aim 2中,我们将使用TLR激动剂和TLR敲除小鼠来确定保护是否通过TLR介导。同样,我们将使用nod样受体(NLR)激动剂和敲除小鼠来确定保护是否通过NLR介导。在Aim 3中,我们将测试枯草芽孢杆菌通过T调节细胞介导保护的可能性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Katherine L. Knight其他文献

Genetic control of alpha chains of rabbit IgA: allotypic specificities on the variable and the constant regions.
兔 IgA α 链的遗传控制:可变区和恒定区的同种异型特异性。
Exopolysaccharide-treated Dendritic Cells Effectively Ameliorate Acute Graft vs Host Disease.
胞外多糖处理的树突状细胞可有效改善急性移植物抗宿主病。
  • DOI:
    10.1016/j.jtct.2023.10.023
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.2
  • 作者:
    O. Kalinina;L. Minter;Anne I. Sperling;M. K. Hollinger;Phong Le;Barbara A. Osborne;Shubin Zhang;Patrick Stiff;Katherine L. Knight
  • 通讯作者:
    Katherine L. Knight
Identification and genetic control of two rabbit high-density lipoprotein allotypes
  • DOI:
    10.1007/bf00486087
  • 发表时间:
    1972-10-01
  • 期刊:
  • 影响因子:
    1.600
  • 作者:
    Alice Gilman-Sachs;Katherine L. Knight
  • 通讯作者:
    Katherine L. Knight
Intestinal bacteria and development of the B-lymphocyte repertoire
  • DOI:
    10.1016/j.it.2005.06.001
  • 发表时间:
    2005-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Dennis K. Lanning;Ki-Jong Rhee;Katherine L. Knight
  • 通讯作者:
    Katherine L. Knight
Contribution of the allelicMtz 3 andMtz 4 allotype genes to the formation of individual rabbit serum α2-macroglobulin molecules
  • DOI:
    10.1007/bf00486080
  • 发表时间:
    1972-10-01
  • 期刊:
  • 影响因子:
    1.600
  • 作者:
    Bernard H. Berne;Sheldon Dray;Katherine L. Knight
  • 通讯作者:
    Katherine L. Knight

Katherine L. Knight的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Katherine L. Knight', 18)}}的其他基金

Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.
使用乳头状瘤假病毒作为载体开发粘膜疫苗以预防艰难梭菌感染。
  • 批准号:
    10213890
  • 财政年份:
    2020
  • 资助金额:
    $ 25.89万
  • 项目类别:
Prevention of GVHD by a probiotic exopolysaccharide.
通过益生菌胞外多糖预防 GVHD。
  • 批准号:
    10081555
  • 财政年份:
    2020
  • 资助金额:
    $ 25.89万
  • 项目类别:
Microbe-driven Development of GALT
微生物驱动的 GALT 开发
  • 批准号:
    10399453
  • 财政年份:
    2018
  • 资助金额:
    $ 25.89万
  • 项目类别:
Microbe-driven Development of GALT
微生物驱动的 GALT 开发
  • 批准号:
    9924442
  • 财政年份:
    2018
  • 资助金额:
    $ 25.89万
  • 项目类别:
Commensal Exopolysaccharide Protection from Inflammation
共生胞外多糖预防炎症
  • 批准号:
    8888736
  • 财政年份:
    2015
  • 资助金额:
    $ 25.89万
  • 项目类别:
Protection from enteric pathogens by beneficial microbes
通过有益微生物预防肠道病原体
  • 批准号:
    8546976
  • 财政年份:
    2012
  • 资助金额:
    $ 25.89万
  • 项目类别:
Somatic Diversification of Immunoglobulin Genes in Galt
Galt 免疫球蛋白基因的体细胞多样化
  • 批准号:
    8321129
  • 财政年份:
    2011
  • 资助金额:
    $ 25.89万
  • 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
  • 批准号:
    7878421
  • 财政年份:
    2009
  • 资助金额:
    $ 25.89万
  • 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
  • 批准号:
    8015990
  • 财政年份:
    2007
  • 资助金额:
    $ 25.89万
  • 项目类别:
Maintaining B cell immunity with aged B lymphocytes
用老化的 B 淋巴细胞维持 B 细胞免疫
  • 批准号:
    7365169
  • 财政年份:
    2007
  • 资助金额:
    $ 25.89万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 25.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 25.89万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 25.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了